TOKYO, May 14 (Pulse News Wire) – Prism Biolab Co.,ltd (206A.T) reported a special loss of ¥24.3 million due to impairment losses related to newly installed equipment during its fiscal second quarter ending March 31, 2026. The impairment loss was recorded as part of the company's efforts to expand research and development capabilities through proactive investments aimed at growing its self-developed and joint venture projects.
As a result, the total special loss for the six-month period ending March 31, 2026, amounted to ¥41.8 million. These figures are reflected in the company’s interim consolidated earnings announcement released today.
The special loss does not impact the operating profit but affects the overall net profit for the period.
🟢 Confidence: High AI-translated content.